FAP and neoplasm: The already existing dosimetry data on FAP targeted radionuclide therapy indicate that the absorbed tumor dose varies between 0.62 ± 0.55, 2.81 ± 1.25, 3.0 ± 2.7 and 6.70 Gy/GBq for [177Lu]Lu-FAPI-04, [90Y]Y-FAPI-46, [177Lu]Lu-FAP-2286 and [177Lu]Lu-DOTAGA.(SA.FAPi)2, respectively [20,23,25,45,53,54,55], supporting the success of the dimeric approach to prolong the retention time of the FAP tracers in tumors.